These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 33015726)

  • 21. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Effects of Sodium-Glucose Cotransporter 2-Inhibitors on Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease or Steatohepatitis and Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials.
    Bica IC; Stoica RA; Salmen T; Janež A; Volčanšek Š; Popovic D; Muzurovic E; Rizzo M; Stoian AP
    Medicina (Kaunas); 2023 Jun; 59(6):. PubMed ID: 37374340
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of Nonalcoholic Fatty Liver Disease (NAFLD) in patients with Type 2 Diabetes Mellitus.
    Portillo-Sanchez P; Cusi K
    Clin Diabetes Endocrinol; 2016; 2():9. PubMed ID: 28702244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease.
    Makri ES; Goulas A; Polyzos SA
    Eur J Pharmacol; 2021 Sep; 907():174272. PubMed ID: 34147478
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antidiabetic Drugs and Statins in Nonalcoholic Fatty Liver Disease.
    Kothari S; Dhami-Shah H; Shah SR
    J Clin Exp Hepatol; 2019; 9(6):723-730. PubMed ID: 31889754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
    Lomonaco R; Sunny NE; Bril F; Cusi K
    Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
    Stein LL; Dong MH; Loomba R
    Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes.
    Bril F; Kalavalapalli S; Clark VC; Lomonaco R; Soldevila-Pico C; Liu IC; Orsak B; Tio F; Cusi K
    Clin Gastroenterol Hepatol; 2018 Apr; 16(4):558-566.e2. PubMed ID: 29223443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Semaglutide combined with empagliflozin vs. monotherapy for non-alcoholic fatty liver disease in type 2 diabetes: Study protocol for a randomized clinical trial.
    Lin YH; Zhang ZJ; Zhong JQ; Wang ZY; Peng YT; Lin YM; Zhang HP; Tian JQ
    PLoS One; 2024; 19(5):e0302155. PubMed ID: 38701096
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of oral antidiabetic agents and incretin mimetics in type 2 diabetic patients with non-alcoholic fatty liver disease.
    Gouni-Berthold I; Papanas N; Maltezos E
    Curr Pharm Des; 2014; 20(22):3705-15. PubMed ID: 24040873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial.
    Cusi K; Orsak B; Bril F; Lomonaco R; Hecht J; Ortiz-Lopez C; Tio F; Hardies J; Darland C; Musi N; Webb A; Portillo-Sanchez P
    Ann Intern Med; 2016 Sep; 165(5):305-15. PubMed ID: 27322798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.
    Dhir G; Cusi K
    J Investig Med; 2018 Jan; 66(1):7-10. PubMed ID: 28918389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis.
    Colosimo S; Ravaioli F; Petroni ML; Brodosi L; Marchignoli F; Barbanti FA; Sasdelli AS; Marchesini G; Pironi L
    Liver Int; 2021 Apr; 41(4):731-742. PubMed ID: 33497019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Khneizer G; Rizvi S; Gawrieh S
    Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhu Y; Xu J; Zhang D; Mu X; Shi Y; Chen S; Wu Z; Li S
    Front Endocrinol (Lausanne); 2021; 12():769069. PubMed ID: 34956080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GLP-1 receptor agonists in the treatment of diabetic non-alcoholic steatohepatitis patients.
    Adeghate EA
    Expert Opin Pharmacother; 2024 Feb; 25(3):223-232. PubMed ID: 38458647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glucagon-Like Peptide 1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Nonalcoholic Fatty Liver Disease Among Patients With Type 2 Diabetes.
    Pradhan R; Yin H; Yu O; Azoulay L
    Diabetes Care; 2022 Apr; 45(4):819-829. PubMed ID: 35104330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of SGLT2 Inhibitors Versus Pioglitazone in the Treatment of Non-alcoholic Fatty Liver Disease or Non-alcoholic Steatohepatitis: A Systematic Review.
    Kaur S; Sojitra V; Zahra A; Hutchinson J; Folawemi O; Bittla P; Ramphall S
    Cureus; 2023 Sep; 15(9):e45789. PubMed ID: 37745748
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 49.